You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Demographics and clinical characteristics of the patient cohort from whom rare NTM were isolated

From: Frequency and clinical implications of the isolation of rare nontuberculous mycobacteria

Demographics N (%)
   Age (year), median (range) 68.0 (30.0–84.0)
   Sex (Male) 39/68 (57.4)
   Body Mass Index (kg/m2), median (range) 22.4 (15.9–29.0)
Habitual factors N (%)
   Smoking 19/68 (33.8)
     Ex-smoker 13/68 (22.4)
     Current smoker 6/68 (10.3)
Past medical history N (%)
   Previous history of TB 24/68 (35.3)
   Sinusitis 9/68 (13.2)
   Measles 3/68 (4.4)
   Pertussis 1/68 (1.5)
Comorbidities N (%)
   Malignancies 7/68 (10.3)
     Lung cancer 1/68 (1.5)
   Diabetes 6/68 (8.8)
   Cerebrovascular disease 2/68 (2.9)
   Rheumatoid arthritis 3/68 (4.4)
   Inflammatory bowel disease 0/68 (−)
   Gastroesophageal reflux 0/68 (−)
   Underlying lung disease  
     COPD 4/68 (5.9)
     Asthma 4/68 (5.9)
     TB-destroyed lung 3/68 (4.4)
     Interstitial lung disease 1/68 (1.5)
     Bronchiectasis 23/68 (33.8)
   HIV infection 1/68 (1.5)
   Post-transplantation status 0/68 (−)
Symptoms N (%)
   Cough 30/68 (44.1)
   Dyspnea 13/68 (19.1)
   Hemoptysis 11/68 (16.2)
   Sputum 39/68 (57.4)
   Fever 6/68 (8.8)
   Myalgia 4/68 (5.9)
   Weight loss 6/68 (8.8)
Physical examination N (%)
   Postnasal drip 10/68 (14.7)
   Crackle 4/68 (5.8)
   Wheezing 1/68 (1.5)
   Murmur 0/68 (−)
   Clubbing 0/68 (−)
   Peripheral edema 0/68 (−)
Drug use  
   TNF-alpha inhibitor* 1/68 (1.5)
   Steroid (5–10 mg daily)* 3/68 (4.4)
   Other immunomodulatory drugs* 2/68 (2.9)
  1. *All these drugs were used for the treatment of patients with rheumatoid arthritis.